

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for July 2026

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Sevmia	Wegovy	SEMAGLUTIDE	4 mg/3 mL (1.34 mg/mL)	solution (subcutaneous)	02569582
Jamp Pharma Corporation	Jamp Oxcarbazepine	Trileptal	OXCARBAZEPINE	150 mg	tablet	02560593
Jamp Pharma Corporation	Jamp Oxcarbazepine	Trileptal	OXCARBAZEPINE	300 mg	tablet	02560607
Jamp Pharma Corporation	Jamp Oxcarbazepine	Trileptal	OXCARBAZEPINE	600 mg	tablet	02560615
Taro Pharmaceuticals Inc.	Taro-Metronidazole Gel	Metrogel	METRONIDAZOLE	0.75% w/w	topical gel	02567342

Apotex Inc.	Apo-Dasatinib Tablets	Sprycel	DASATINIB	20 mg	tablet	02562464
Apotex Inc.	Apo-Dasatinib Tablets	Sprycel	DASATINIB	50 mg	tablet	02562472
Apotex Inc.	Apo-Dasatinib Tablets	Sprycel	DASATINIB	70 mg	tablet	02562480
Apotex Inc.	Apo-Dasatinib Tablets	Sprycel	DASATINIB	80 mg	tablet	02562499
Apotex Inc.	Apo-Dasatinib Tablets	Sprycel	DASATINIB	100 mg	tablet	02562502